Opus Genetics, Inc. (IRD) Current Ratio
- Current ratio · latest quarter: Value 12.19×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 12.19× | Current assets / current liabilities. $92.70M ÷ $7.61M ≈ 12.19× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 92.70M USD | Assets, Current |
| Current obligations | 7.61M USD | Liabilities, Current |
| Cash and equivalents | 88.81M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 1.04M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.88M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $92.70M | $7.61M | $88.81M | (m) | $1.04M | (m) | $1.88M | (m) | 12.19× |
| 2026-03-31 | $66.60M | $9.34M | $59.96M | (m) | $1.73M | (m) | $4.42M | (m) | 7.13× |
| 2025-12-31 | $50.04M | $7.78M | $45.09M | (m) | $2.00M | (m) | $3.29M | (m) | 6.43× |
| 2025-09-30 | $35.91M | $29.09M | $30.82M | (m) | $2.92M | (m) | $2.40M | (m) | 1.23× |
| 2025-06-30 | $38.44M | $20.19M | $32.43M | (m) | $3.40M | (m) | $1.47M | (m) | 1.90× |
| 2025-03-31 | $47.93M | $24.25M | $41.79M | (m) | $3.08M | (m) | $2.43M | (m) | 1.98× |
| 2024-12-31 | $36.61M | $11.29M | $30.32M | (m) | $3.56M | (m) | $3.15M | (m) | 3.24× |
| 2024-09-30 | $40.39M | $6.09M | $36.63M | (m) | $1.86M | (m) | $844.00K | (m) | 6.63× |
| 2024-06-30 | $44.83M | $4.20M | $41.41M | (m) | $1.36M | (m) | $634.00K | (m) | 10.68× |
| 2024-03-31 | $51.84M | $5.79M | $47.16M | (m) | $1.92M | (m) | $2.06M | (m) | 8.96× |
| 2023-12-31 | $53.95M | $4.04M | $50.50M | (m) | $926.00K | (m) | $2.15M | (m) | 13.35× |
| 2023-09-30 | $54.19M | $3.91M | $42.35M | (m) | $10.13M | (m) | $1.89M | (m) | 13.86× |
| 2023-06-30 | $43.46M | $5.76M | $39.98M | (m) | $135.00K | (m) | $2.32M | (m) | 7.54× |
| 2023-03-31 | $45.40M | $4.15M | $38.99M | (m) | $2.83M | (m) | $2.22M | (m) | 10.93× |
| 2022-12-31 | $48.99M | $2.75M | $42.63M | (m) | $1.30M | (m) | $1.07M | (m) | 17.79× |
| 2022-09-30 | $14.56M | $2.69M | $13.86M | (m) | (m) | (m) | $1.47M | (m) | 5.41× |
| 2022-06-30 | $17.89M | $3.30M | (m) | (m) | (m) | (m) | $1.89M | (m) | 5.41× |
| 2022-03-31 | $20.48M | $3.21M | (m) | (m) | (m) | (m) | $1.58M | (m) | 6.37× |
| 2021-12-31 | $26.07M | $3.85M | $24.53M | (m) | $0.00 | (m) | $1.58M | (m) | 6.76× |
| 2021-09-30 | $23.19M | $2.64M | (m) | (m) | (m) | (m) | $1.43M | (m) | 8.79× |
| 2021-06-30 | $25.24M | $2.70M | (m) | (m) | $50.00K | (m) | $1.50M | (m) | 9.35× |
| 2021-03-31 | $12.11M | $2.31M | (m) | (m) | (m) | (m) | $1.42M | (m) | 5.24× |
| 2020-12-31 | $17.67M | $3.19M | (m) | (m) | (m) | (m) | $1.21M | (m) | 5.55× |
| 2020-09-30 | $8.65M | $3.01M | (m) | (m) | (m) | (m) | (m) | (m) | 2.88× |
| 2020-06-30 | $10.03M | $2.98M | (m) | (m) | (m) | (m) | (m) | (m) | 3.37× |
| 2020-03-31 | $11.29M | $1.98M | (m) | (m) | (m) | (m) | (m) | (m) | 5.70× |
| 2019-12-31 | $1.76M | $9.34M | (m) | (m) | (m) | (m) | $342.00K | (m) | 0.19× |
| 2019-09-30 | $14.64M | $3.00M | (m) | $5.98M | (m) | (m) | (m) | (m) | 4.88× |
| 2019-06-30 | $17.29M | $3.55M | (m) | $8.95M | (m) | (m) | (m) | (m) | 4.87× |
| 2019-03-31 | $18.99M | $2.51M | (m) | $11.89M | (m) | (m) | (m) | (m) | 7.57× |
| 2018-12-31 | $15.90M | $3.15M | (m) | $5.98M | (m) | (m) | (m) | (m) | 5.04× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |